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An early cellular event in the development of psori­
atic lesions is infiltration of target tissue by macro­
phages and activated T lymphocytes. Lesional psori­
atic skin contains activated memory T lymphocytes 
with production of mRNA for lymphokines such as 
interleuldn-2, interferon-y, and tumor necrosis fac­
tor-a that is elevated relative to normal or unin­
volved psoriatic skin. That the T-cell activation and 
cellular lymphokine production have a crucial role in 
the mainten�ce of epidermal hyperplasia in the 
psoriatic lesion is indicated by the beneficial effect of 
immunosuppressive agents in the treatment of psori­
asis (cyclosporin A, FK.506, anti-CD3, anti-CD4). A 
link between immune activation and psoriasis is also 
indicated by immunogenetic associations in this dis­
ease. Also, psoriatic keratinocytes appear to have 
been modulated by T-cell lymphokines in vivo, be­
cause they abnormally express Dlolecules uniquely 
induced on keratinocytes by the T-cell product inter­
feron-y. Indeed, T cells producing interferon-y have 
been cloned from psoriatic lesions, and they are able 
to induce keratinocyte class II major histocompati­
bility complex and intercellular adhesion molecule 
expression. These lesion-derived T-cell clones can 
P soriasis renders the skin susceptible to being stimulated into a self-propagating state of hyperproliferation. . Many stimuli can initiate the reactions leading to pso­riasis, ranging from infections to physical trauma to contact allergic dermatitis to stress. Here, we review 
recent evidence indicating which cells in the proliferative compart­
ment of the epidermis are the source of hyperproliferation in 
psoriasis and how these epidermal keratinocyte stem cells are 
hyperresponsive to lyrnphokine combinations released by activated 
T cells from psoriatic lesions. 
EVIDENCE FOR AN IMMUNOLOGIC COMPONENT IN 
THE INDUCTION OF THE PSORIATIC KERATINOCYTE 
HYPERPROLIFERATIVE STATE 
It is now clear from bone marrow transplants that cells of the 
immune system can be responsible for the appearance or disappear­
ance of psoriasis [1,2]. From studies using cyclosporin A, FK 506, 
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lnununodennatology Unit, R5548 Kresge I/Campus Box 0530, Ann Arbor, 
MI 48109-0530. 
Abbreviation: PCNA, proliferating cell nuclear antigen. 
induce growth of keratinocytes, and specifically le­
sional psoriatic T cells produce factors that induce 
increased keratinocyte colony formation, as well as 
increased cell cycle entry of the normally quiescent 
stem cell population. Interferon-y, although a 
growth inhibitor on its own, acts cooperatively with 
other T -cell-produced growth factors to caqse kera­
tinocyte growtJt induction. Furthermore, relative to 
normal stem cells, keratinocyte stem cells (111 inte­
grin+ K11K10-) in psoriatic uninvolved epidermis are 
significantly hyperresponsive to the growth-stimula­
tory lymphokine milieu created by lesional T lym­
phocytes. Whether such abnormalities in responsive­
ness are associated with new genetic linkages reported 
in families of psoriasis patients is unknown. As the 
epidermis of lesional psoriatic skin can be demon­
strated to produce elevated levels of facton; that can 
further potentiate T-cell activation, a self-sustaining 
cycle can be constructed ofT-cell recruitment, intrale­
sional activation, release of factors that preferentially 
stimulate psoriatic epidermal stem cells to proliferate, 
and further epidermal potentiation of the T -cell-medi­
ated lesions.] Invest Dermato1105:89S-94S, 1995 
anti-CD3, and anti-CD4, it is also clear that T cells, in particular, 
are a critical component of at least one of the self-propagating loops 
in psoriasis [3-9] . * 
Involvetnent ofLesional T Cells One of the earliest events in 
the pathologic changes occurring in psoriasis is the appearance ofT 
cells and macrophages in psoriatic skin lesions [10-14]. The 
epidermal psoriatic lesional T-cell population consists primarily of 
activated helper T cells [11,14-19] of memory phenotype [19], 
whose production of mRNA for lyrnphokines such as interleukin-2 
(IL-2), interferon-/, (IFN-/,), and tumor necrosis factor-a (TNF-a) 
is elevated relative to normal or uninvolved psoriatic epidermis 
[20]. Whereas in early and fully developed lesions, CD4+celis are 
predominant, in spontaneously resolving lesions CDS + T cells 
become more prominent [21,22]. Physical injury to the psoriatic 
uninvolved skin does not always lead to induction of the disease 
(Koebner phenomenon), but when it does, it has been associated 
with a predominance of CD4+ over CDS+ T cells in the epidermis 
[23]. It has also been shown that human CD4+ T lymphocytes 
* Ackennan C, Abu-Elagd K, Venkataramanan K, FungJ, Todo S, Starzl 
T, ]egasothy B: Recalcitrant psoriasis and pyodenna gangrenosum treated 
with FK506 (abstr). ] Invest Dermatol 96:536, 1991. 
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Figure 1. Intl'alesional T-cell activation and subsequent Ipnpbo­
kine pl'oduction. Keratinocyte stem cells could be induced to leave cell 
quiescence and enter the cell cycle. resulting in an expansion of the 
proliferative keratinocyte cell compartments. Increased levels of cytokines 
produced by keratinocytes could further enhance T-cell infiltration. leading 
to a self-sustaining cycle. T ACs. transient amplifying cells; DEJ. derrnoepi­
dennal junction. 
adhere preferentially to psonatlc (compared with normal) skin 
sections (24]. Clearance of these memory T cells precedes clinical 
improvement by several treatments [25]. including immunosup­
pressants [3.14.26]. By contrast, cyclosporin A therapy does not 
reduce epidermal hyperplasia in the absence of aT-cell-activation 
component (27], and extremely high. nonphysiologic concentra­
tions are required to inhibit keratinocyte proliferation direcdy in 
vitro (reviewed in [28]). 1L-2 and IFN-y. both T-cell-specific 
lymphokines, can induce the appearance of psoriasis upon admin­
istration in vivo to patients with a propensity for psoriasis (29.30]. 
Psoriatic keratinocytes do appear to have been modulated by 
T-cell lymphokines in vivo because they externally express class II 
major histocompatibility complex (MHC) and IF-10. molecules 
uniquely induced on keratinocytes by IFN-y (31-35]. Indeed. T 
cells producing IFN-y have been cloned from psoriatic lesions 
[36.37], and they appear to be able to induce keratinocyte class II 
MHC and intercellular adhesion molecule expression [38] and in 
vitro growth of semiconHuent (37] or multiply passaged (39] normal 
keratinocytes. Thus, T cells are a likely source of signals for 
keratinocyte activation. either directly or indire-cdy. 
Involvement of Altered Antigen-Presenting Cells (APCs) 
For intralesional T-cell activation to occur, the lymphocyte must 
interact with lesional APCs. Lesional psoriatic epidennis possesses 
an elevated alloantigen-presenting capacity [34] and an abnormal 
ability to stimulate autologous T cells in the absence of exogenous 
antigens [40-42].t The stimulating cell in both assays belongs to a 
bone-marrow- derived CD1a - (non-Langerhans cell) human leu­
kocyte antigen (HLA)-DR + population [34A1] that expresses 
macrophage markers [14.34]. The APC activity is not due to 
HLA-DR + kera.tinocytes, which are also abnormally present [34]. 
Using simultaneous visualization by irnmunolalbeling and autora­
diography of psoriatic skin injected in vivo with 3H-UdR, memory 
T c'ells were often observed in direct apposition to cells bearing a 
macrophage marker not expressed on Langerhans cells. This find­
ing provides additional ilt vivo support for the concept that infiltrat­
ing macrophage cells provide signals for direct intralesional T-cell 
activation [19]. Lesional psoriatic epidermal cells. but not normal 
cells. release a balance of cytokines that potentiate T-cell activation 
[43] (Fig 1). 
t Gonzalez-Ramos A. Wallner BP. Voorhees JJ. Cooper KD: APC­
targeted immunointervention in psoriasis : blockade of LFA3-CD2 and 
ICAM1-LFA1 ligand pairing blocks autoreactivity to lesional epidermis 
(abstr) .] Invest Dermatal 98:556. 1992. 
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During cyclosporin A therapy of psoriasis. APC activity decreases 
in the epidennis and correlates closely with both resolution of the 
lesion and reduction in the number of abnormal CD1a - HLA-DR + 
cells in the psoriatic lesion [4.14.44,45]. 
OTHER FACTORS LEADING TO ENHANCED LEVELS OF 
LESIONAL T-CELL ACTIVATION 
Why do APC interactions with T lymphocytes lead to T-cell 
activation in psoriatic skin but not in normal skin? A number of 
factors may convert low-affinity T -cell-receptor recognition of self 
peptides bound within either class II MHC or class I MHC 
molecules on APCs [46]. For instance. we have demonstrated that, 
although the intracellular compartment of psoriatic lesional kerati­
nocytes is dominated by an extremely high ratio of the intracellular 
1L-1 receptor antagonist [47] to IL-1 [48]. these same keratinocytes 
excrete into their extracellular milieu a mix of irnmunostimulatory 
cytokines in which 1L-1 activity dominates over antagonism 
[43,47]. In contrast to normal epidennis, which releases a balance 
of cytokines that is neither immunostimulatory nor inhibitory. the 
cytokines released by psoriatic epidennis strongly potentiate T-cell 
activation in response to a suboptimal T -cell-receptor-mediated 
signal [43]. Both IL-1 and 1L-8 were implicated in this response, 
and indeed IL-8. as well as IL-6. GRO-a, and MCP-1 (other 
T-cell-stimulatory cytokines). can be elevated in lesional psoriatic 
skin [49-51].=1= 
Another mechanism by which T -cell-receptor low-affinity inter­
actions may become productive for T-cell activation could be 
through immunogenetically determined high-risk MHC (Le .• Cw6) 
[52-56] molecule binding of certain self peptides. which may be 
induced or overexpressed in psoriasis to sufficient degree for T-cell 
activation. The prevalence of certain V{3-expressing families in 
lesional skin and the enrichment of CD8+ lymphocytes in psoriatic 
epidermis. particularly in human immunodeficiency virus lllV­
related disease. may be consistent with class I MHC triggering [46]. 
Along this same line of thought, microbial antigens. in particular 
superantigens. may provide a stimulus for breaking through a 
subthreshold level of T -cell-receptor interaction in psoriatic skin 
[57.58].§ 
EVIDENCE OF L YMPHOKINE EFFECT ON 
KERATINOCYTE GROWTH 
Both IL-3 and granulocyte-macrophage colony-stimulating factor 
(GM-CSF) have been reported to be growth-promoting factors for 
keratinocytes in vivo [59]�** as well as in vitro on passaged cells [60]. 
IFN-y has been shown to inhibit normal and. to a lesser degree, 
psoriatic epidermal cell growth in vitro in primary cultures [61.62]. 
despite its ability to induce the keratinocyte mitogen transforming 
growth factor-a [63]. However, IFN-y administered in vivo to 
psoriatic uninvolved skin resulted in hyperproliferation of the 
epidermis [30]. Recent investigations into other lymphokines 
showed that T cells can produce heparin-binding epidermal growth 
factor-like growth factor [64] and that activated y/8 T cells 
obtained from mouse skin and intestine prod)lce the epithelial cell 
mitogen keratinocyte growth factor [65]. 
:j: Grossman RM. Gottlieb AB. Sehgal PB. Krueger J. May LT. Kupper T. 
Murphy DP. Ray A: Increased 1L-6 in psoriatic plaques (abstr). Clin Ra 
37:691A. 1989. 
§ Walsh p. Abe J. Giomo R. Norris DA. Leung DYM: Selective 
stimulation of Vbeta5 . 1 + T cells following stimulation with candida 
albicans in vivo and in vitro (abstr) . Clin Res 40: 11A. 1992. 
� Smith CH, Groves RW. Ross IL. Barker JNWN. MacDonald DM: 
Effect of granulocyte macrophage-colony stimulating factor (GM-CSF) on 
Langerhans cells in vivo (abstr).] Invest DermataI100:490. 1993. 
** Schwartz M. Braunstein S, Kaplan G. Cohn Z, Gottlieb AB. Krueger 
JG: GM-CSF activates regenerative epidermal growth and stimulates kera­
tinocyte proliferation in human skin in vivo (abstr).] Invest Dermata! 
100:494. 1993. 
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Table I. Multiparameter Flow Cytometry Identification of Distinct Epidermal Compartmentsa 
Epidermal Cell 
Compartment 
Basal stem cell 
Transitional cell 
Transient amplifying cell 
Differentiating supra-
basal 
Percent in S/G2/M 
4.5 
49 
0 
Percent in Go/t /3, Integrin 
95.5 + 
+ 
51 + 
100 
/3. Integrin KI/K10 Granularity Size 
+ Low Small 
Low Small 
+ High Large 
+ High Large 
a Nonnal epidennal cells were isolated from keratome biopsy specimens and fixed in 70% ethanol, then co-stained with antibodies to 13, integrin, 134 integrin, KI/KI0, PCNA, 
and the DNA dye propidium iodide in diJferent combinations. 
INCREASED PSORIATIC KERATINOCYTE 
PROLIFERATION IS LOCALIZED TO 131 INTEGRIN+ Kl/ 
KI0- CELLS 
Psoriatic epidermal hyperplasia is thought to be due in part to an 
increase in the number of keratinocytes in the proliferative pool, 
possibly because of a shorter psoriatic keratinocyte G1 phase of the 
cell cycle [66,67] as well as increased Go to G1 recruitment [68]. 
We have recently been able to define much more precisely the 
keratinocyte compartment within psoriatic epidermis that is in the 
hyperproliferative state [69]. This was contingent upo� 0U: use of 
flow cytometric analysis of cycling cells (greater than diplOId DNA 
content) in combination with monoclonal antibody staining of 
subsets (anti-131 integrin [CD29], anti-134 basal cell basal aspect 
integrin, and anti-differentiation keratin K1IKI0), which .allo�ed us to define the major basal/immediately suprabasal proliferatlve 
keratinocyte compartments in the epidermis. Thus, 131 integrin + 134 
integrin + KIIKIO- cells appear to represent slowly cycling non­
dilferentiating basal stem cells based on their small size, simple 
cytoplasm, lack of evidence of terminal differentiation, and pre­
dominantly noncycling states (less than 5% expressing the
. 
G1 
auxiliary DNA polymerase, proliferating cell nuclear antlgen 
[PCNA], or in S/G2/M by DNA content). These features are 
highly characteristic of those of in vivo human epidermal st�m ce.
lls 
described by other methods [70,71]. We were also
_
able to lde�tify 
and quantitate 13 integrin + 134 integrin - Kl/KI0 cells (possIbly , 
d a· · + a post-stem transitional keratinocytes) (Table I) an PI mtegrm P4 
integrin - Kl /Kl 0 + cells, which represent the transient amp�g 
cell population committed to differentiation (Kl/KI0 expresslOn) 
and which contain the highest proportion of cycling cells in normal 
epidermis (Table I) [69]. 
A major and highly consistent change in the stem-ceIl-contain­
ing population was detected as increased cycling cell numbers 
among the 13, integrin + Kl/KI0- basal stem cells in psoriatic 
epidermis, whereas the numbers of cycling 131 integrin + Kl/KI0+ 
transient amplifying cell population were sinrilar in psoriatic and 
normal epidermis [69]. Thus, among the 13, integrin + Kl/KI0-
epidermal cells, only 4.5% showed positive staining with anti­
PCNA in normal epidermis, indicating that the vast majority of 
these cells were in a quiescent state (Go/early G,). However, in 
lesional psoriatic epidermis, all of the 13, integrin + Kl/KI0- cells 
exhibited high PCNA levels, indicating that all of these cells had 
been induced into the cell cycle [69]. These data suggest that the 
most likely relevant target population for a putative link between 
lymphokines released by activated T lymphocytes and keratinocyte 
hyperproliferation would be the basal (134 integrin +, 13, integrin +, 
K1IKI 0- , PCNA -) cell of stem cell phenotype. 
DEVELOPMENT OF AN IN VITRO ASSAY FOR 
DETERMINING CHANGES IN PROLIFERATION AMONG 
DEFINED EPIDERMAL KERATINOCYTE 
SUBPOPULATIONS 
Based upon our establishment of methodology allowing quantita­
tion of proliferation rates within subsets of the proliferative pool of 
freshly obtained human epidermal cells, we then developed an in 
vitro assay to model the in vivo effects of T-cell lymphokines upon 
keratinocyte-subset growth. Because we identified the primary cell 
source of hyperproliferation in psoriasis to be �thin the s�em-c�11-
containing population, we were particularly mterested � tes�g 
whether T -cell lymphokines, if they were successful at stJ.mulatJ.ng 
keratinocyte growth, would preferentially stimulate the keratino­
cyte subset responsible for hyperproliferation in psoriatic skin. 
By using freshly isolated epidermal cells in fresh ex vivo culture, 
we planted a synchronized population of stem cells in Go. After 24 
h of culture, epidermal cells exhibited the same characteristics by 
flow cytometry as freshly isolated epidermal cells. Essentially all 
proliferating cells were 13, integrin +. The proliferating population 
(131 integrin +) could be divided into two proliferating cell popula­
tions by their Kl/KI0 expression; the majority of the proliferative 
compartment (S/G2/M) was Kl/KI0+. 
After 72 h of culture, a distinct proliferating cell population 
began to appear, which had very bright 13, integrin express�on. 
After 7 d in culture, almost all of the cells were 13, integrinbngbt, 
Kl/KI0-, and had attained a very high proliferative rate. At 
culture confluence, and consistent with the phase microscopic 
appearance of differentiation, Kl /Kl 0 expression and decreased 131 
integrin levels were evident in the majority of the cells. At 
confluence, the proliferation rate of the cells in the confluent culture 
had slowed down. Concordantly, only a few cells were 131 integrin - in 
the confluent culture (6.9%) and the vast majority were now express­
ing KIIKIO (81.5%), indicative of a transient amplifYing cell-like 
+ + h gh  all a ·  . +  phenotype (131 integrin Kl/KI0), alt ou a sm PI mtegrm 
Kl/KI0- stem cell population remained in the culture [72]. 
These observations suggest that epidermal cell growth in fresh ex 
vivo culture was initiated by cells that exhibit the in vivo stem cell 
phenotype (131 integrin + Kl/KI0-). In vivo, these ce�s pro�erate 
at a very low rate, but in culture they are transIently highly 
proliferative. After the initial die-off of existing differentiated cells 
(Kl/KI0+), the stem-cell-containing population (131 integrin + 
Kl/KI0-) expands through increased proliferation, followed by 
differentiation to Kl/KI0+ cells. Subsequent proliferation is then 
mainly by 131 integrin + Kl /Kl 0 + cells until further differentiation 
and nonproliferative starns are achieved. The 13, integrin + K1/ 
KI0+ phenotype is characteristic of the population in in vivo 
epidermis, which undergoes amplification while beginning terminal 
differentiation (transient amplifying cells). The remaining 13, inte­
grinbright, Kl/KI0- cell population in the confluent culture repre­
sents those cells that maintain a stem cell phenotype in the culture, 
consistent with a recent report using sinrilar methodology to 
characterize multiply passaged keratinocyte cul.tures propagated on 
collagen in serum [73]. Indeed, 131 integrinbnght cells have been 
localized to areas of basal keratinocytes enriched in stem cells [74]. 
Manipulation of our fresh ex vivo culture system, which we 
believe is the most relevant and precise keratinocyte growth assay 
we have yet examined for this purpose, provided us with a means 
of quantitating the growth effects ofT -celllymphokines upon these 
specific subpopulations present within in vivo human epidermis. 
T CELLS CLONED FROM PSORIATIC LESIONS CAN 
EXERT A POSITIVE INFLUENCE ON KERATINOCYTE 
CLONAL GROWTH 
Before our development of the above assay, we had used a clonal 
growth assay of freshly obtained keratinocytes to determine the 
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effect of lymphokines of psoriatic involved T oells cloned from an 
untreated, expanding lesion under low 1L-2 conditions (which 
selects for intralesionally ill vivo-activated T celUs expressing high­
affinity IL-2 receptor) [38]. These cloned T cells were then 
activated by stimulation with immobilized anti-CD3 and fibronec­
tin [43], and their supernatants were harvested. The lymphokine 
profiles of these supernatants were assessed :and related to the 
capacity of each cloned T -cell line to modulate the clonal growth 
assay of primary cultured keratinocytes from psoriatic uninvolved 
skin. The T cells could be grouped into three c3ltegories: those that 
potentiated keratinocyte growth, those that had no effect, and those 
that inhibited keratinocyte colony formation [72]. T cells with a 
growth-potentiating effect or no effect were all CD4 +, whereas T 
cells producing inhibitory lymphokines were composed of CD8+ 
and CD4- CD8- yl8 T-cell receptor- altl T-cell receptor+ 
lymphocytes. High GM-CSF and IFN-y levels were characteristic 
of both growth-stimulatory and growth-inhibitory T-cell superna­
tants. Growth inhibition correlated with the occurrence of high 
IL-3 and moderate tumor necrosis factor-a lev<els in T-cell super­
natants. These data are compatible with other findings indicating 
that T-cell products can positively influence th,e growth of ill vitro 
cultured keratinocytes [37,39]. 
KERATINOCYTE CLONAL GROWTH-STIMULATORY 
PSORIATIC LESIONAL T-CELL LYMPHOKINES ENHANCE 
PROLIFERATION OF PSORIATIC UNIl'IrvOLVED BUT 
NOT NORMAL STEM KERATINOCYTES 
Having demonstrated that the stem cell «(31 integrin + K1/K10-) is 
the primary hyperproliferative population in the ill vivo epidermis of 
psoriatic lesions and that an analogous population of stem cells «(31 
integrin + K1/K10-) can be identified in the early stages (first 
week) of a primary ill vitro epidermal cell culture, we then asked 
whether growth-stimulatory T-cell supernatants: act directly on the 
(31 integrin+ KlIK10- stem cell population. In seven of seven 
experiments using different uninvolved psoriatic epidermal cells, 
supernatants of activated psoriatic lesional T cells stimulated 
slightly to greatly increased cycling of (31 integrinbright cells (p = 
0.01), as well as increased numbers of these cellls (p = 0.009). By 
contrast, epidermal cells from all six normal :lUbjects stimulated 
with the same T-cell supernatant did not show increased numbers 
of (31 integrinbright cells in the cycle (p = 0.66) or an increase in the 
proportion of these cells. Thus, by focusing our analysis on a 
relevant biologic readout on the appropriate minor cell subset, we 
could reproducibly quantitate, in an ill vitro assay, a growth­
promoting effect of T-cell lymphokines upon the specific keratino­
cyte population «(31 integrin + K1 IK1 0 -) that is in a hyperprolif­
erative state in psoriatic lesions (Fig 1). Of additional and critical 
importance, our data also demonstrated that (31 iltltegrin + KlIK10-
keratinocytes from uninvolved skin of psoriatic individuals are 
hyperresponsive in their response to T-cell lymphokines relative to 
the stem cells of normal subjects. Thus, perhaps of strong relevance 
to the Koebuer phenomenon in psoriasis, the stem cells in unin­
volved skin of psoriatics are poised to hypenrespond to signals 
deriving from lymphocyte activation, such as may occur in infec­
tions and wounds. 
ANTmODY NEUTRALIZATION STUDIES: A CRITICAL 
ROLE FOR IFN--y 
We performed neutralizing antibody experiments to identify the 
lymphokine(s). responsible for stimulating increases in the numbers 
of (31 integrinbright cells and increases in their proliferation (increas­
es in the number of (31 integrinbright cells in S/G2M of the cell 
cycle). Only the neutralizing antibody against ][FN--y consistently 
reduced the T -cell-supernatant-stimulated increase in (31 inte­
grinbrigbt cells relative to isotype control antibodies . Concurrent 
with the reduction in (31 integrinbrigbt cells, a simiilar reduction of (31 
integrinbright cells in the cycle occurred in the presence of IFN-y 
neutralizing antibodies. Addition of anti-IFN--y to the psoriatic 
uninvolved epidermal cell cultures did not charlge the number or 
proliferative capacity of vimentin + cells in the cultures, which 
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could also express bright (31 integrin [72], indicating that melano­
cyte (and possibly Langerhans cell) proliferation is IFN--y indepen­
dent. Thus, keratinocytes are a specific target of growth stimulation 
by IFN-y [37,72]. 
Despite previous reports indicating keratinocyte growth-promot­
ing properties of GM-CSF and 1L-3 [60], no consistent growth 
inhibition occurred in the presence of neutralizing antibodies to 
GM-CSF or 1L-3. In addition, the presence of neutralizing anti­
GM-CSF or anti-IL-3 without the growth-stimulating T-cell su­
pernatant did not affect the numbers of (31 integrinbright cells [72}, 
suggesting that autocrine production of these lymphokines by 
keratinocytes was not responsible for growth regulation [75,76]. 
RECOMBINANT L YMPHOKINE STUDIES: COOPERATIVE 
ACTION OF GROWTH FACTORS CONVERTED IFN-y 
FROM AN INHIBITOR TO A STIMULATOR OF STEM 
CELL GROWTH 
To determine whether IFN--y alone was responsible for the ill vitro 
growth-stimulatory effect on psoriatic uninvolved (31 integrinbright 
stem cells, we cultured psoriatic uninvolved epidermal cells sup­
plemented with human recombinant IFN-y at various concentra­
tions. Contrary to expectations derived from our antibody-neutral­
izing studies, we found that recombinant IFN--y suppressed growth 
of the (31 integrinbright cells. Thus, by itself, recombinant IFN-'l' 
suppressed expansion of the (31 integrinbright stem cell population in 
the uninvolved epidermal cells, similar to its action on multiply 
passaged keratinocytes [63]. 
To resolve these paradoxic results , we determined whether 
GM-CSF and/or 1L-3, which are concomitantly present in the 
T-cell supernatants, could reverse the recombinant IFN-y inhibi­
tory effect. Indeed, GM-CSF and 1L-3 converted IFN-y from a 
growth-inhibitory lymphokine to a stem-cell growth-stimulating 
lymphokine when all three were added t ogether to psoriatic 
uninvolved epidermal cell cultures. However, GM-CSF or IL-3 by 
themselves were incapable of stimulating increased growth of (31 
integrinbright stem cells. These experiments indicate not only a 
critical role for IFN-y in regulating psoriatic uninvolved (31 inte­
grinbright stem cell growth, but also that the effects ofIFN-y upon 
this population are modified by the presence of GM-CSF and IL-3. 
Such results are consistent with other (nonepithelial) stem cell 
models in which the cooperative action of cytokines differs from 
their actions in isolation [77-80]. 
CONCLUSION 
The data reviewed here strongly support the hypothesis that 
lesional psoriatic T cells activated intralesionally initiate epidermal 
hyperplasia via keratinocyte stem cell induction into the cell cycle, 
resulting in expansion of all the various proliferative compartment 
populations . Because epidermal hyperproliferation is a key patho­
logic phenomenon in psoriasis, uncovering its triggering mecha­
nisms is fundamental to further understanding and therapeutic 
research in the disease. 
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